BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
Bio-Techne (NASDAQ: TECH) reported Q1 FY2025 results with organic revenue growth of 4% (5% reported) to $289.5 million. GAAP EPS decreased to $0.21 from $0.31 year-over-year, while adjusted EPS slightly increased to $0.42 from $0.41. The Diagnostics & Spatial Biology segment showed strong performance with 14% organic growth. The Protein Sciences segment remained flat at $204.5 million with 1% organic growth. GAAP operating margin declined to 13.8% from 20.2%, while adjusted operating margin decreased to 29.0% from 31.4% due to product mix and compensation accruals.
Bio-Techne (NASDAQ: TECH) ha riportato i risultati del primo trimestre dell'anno fiscale 2025 con una crescita dei ricavi organici del 4% (5% riportato), raggiungendo 289,5 milioni di dollari. L'EPS GAAP è diminuito a $0,21 da $0,31 rispetto all'anno precedente, mentre l'EPS rettificato è leggermente aumentato a $0,42 da $0,41. Il segmento Diagnostica e Biologia Spaziale ha mostrato una forte performance con una crescita organica del 14%. Il segmento Scienze delle Proteine è rimasto stabile a 204,5 milioni di dollari con una crescita organica dell'1%. Il margine operativo GAAP è sceso al 13,8% dal 20,2%, mentre il margine operativo rettificato è diminuito al 29,0% dal 31,4% a causa della variazione del mix di prodotti e degli accantonamenti relativi alle compensazioni.
Bio-Techne (NASDAQ: TECH) reportó los resultados del primer trimestre del año fiscal 2025 con un crecimiento orgánico de ingresos del 4% (5% reportado), alcanzando 289.5 millones de dólares. El EPS GAAP disminuyó a $0.21 desde $0.31 en comparación con el año anterior, mientras que el EPS ajustado aumentó ligeramente a $0.42 desde $0.41. El segmento de Diagnósticos y Biología Espacial mostró un desempeño fuerte con un crecimiento orgánico del 14%. El segmento de Ciencias de las Proteínas se mantuvo estable en 204.5 millones de dólares con un crecimiento orgánico del 1%. El margen operativo GAAP cayó al 13.8% desde el 20.2%, mientras que el margen operativo ajustado disminuyó al 29.0% desde el 31.4% debido a la mezcla de productos y acumulaciones de compensación.
바이오텍네 (NASDAQ: TECH)는 2025 회계연도 1분기 실적을 보고하며, 유기 수익이 4% 증가(보고된 수치는 5%)하여 2억 8950만 달러에 도달했다고 발표했습니다. GAAP 기준 주당 순이익(EPS)은 작년의 $0.31에서 $0.21로 감소했고, 조정된 EPS는 $0.41에서 $0.42로 약간 증가했습니다. 진단 및 공간 생물학 부문은 14%의 유기 성장을 보이며 강력한 성과를 나타냈습니다. 단백질 과학 부문은 2억 4450만 달러로 유지되었으며, 유기성장률은 1%에 불과했습니다. GAAP 운영 마진은 20.2%에서 13.8%로 감소했고, 조정된 운영 마진은 제품 믹스와 보상 적립금으로 인해 31.4%에서 29.0%로 감소했습니다.
Bio-Techne (NASDAQ: TECH) a annoncé les résultats du premier trimestre de l'exercice 2025 avec une croissance organique des revenus de 4% (5% rapporté) atteignant 289,5 millions de dollars. Le BPA GAAP a baissé à 0,21 $ contre 0,31 $ l'année précédente, tandis que le BPA ajusté a légèrement augmenté à 0,42 $ contre 0,41 $. Le segment Diagnostics et Biologie Spatiale a montré une forte performance avec une croissance organique de 14%. Le segment Sciences des Protéines est resté stable à 204,5 millions de dollars avec une croissance organique de 1%. La marge opérationnelle GAAP a diminué à 13,8% contre 20,2%, tandis que la marge opérationnelle ajustée a diminué à 29,0% contre 31,4% en raison du mix de produits et des provisions pour salaires.
Bio-Techne (NASDAQ: TECH) hat die Ergebnisse des 1. Quartals des Geschäftsjahres 2025 mit einem organischen Umsatzwachstum von 4% (5% berichtet) veröffentlicht, was 289,5 Millionen Dollar entspricht. Der GAAP Gewinn pro Aktie (EPS) sank von $0,31 auf $0,21 im Jahresvergleich, während der bereinigte EPS leicht von $0,41 auf $0,42 stieg. Das Segment Diagnostik und räumliche Biologie zeigte eine starke Leistung mit einem organischen Wachstum von 14%. Das Segment Proteinwissenschaften blieb mit 204,5 Millionen Dollar und 1% organischem Wachstum stabil. Die GAAP Betriebsmarge fiel auf 13,8% von 20,2%, während die bereinigte Betriebsmarge aufgrund der Produktmix und der Rückstellungen für Vergütungen auf 29,0% von 31,4% sank.
- Organic revenue increased 4% to $289.5 million
- Diagnostics & Spatial Biology segment achieved 14% organic growth
- Adjusted EPS improved to $0.42 from $0.41 year-over-year
- Strong growth in GMP reagent portfolio
- GAAP EPS declined to $0.21 from $0.31 year-over-year
- GAAP operating margin decreased to 13.8% from 20.2%
- Adjusted operating margin fell to 29.0% from 31.4%
- Protein Sciences segment showed flat growth at $204.5 million
Insights
Bio-Techne's Q1 FY2025 results show mixed performance with some concerning trends. While revenue grew
The bright spot is the Diagnostics & Spatial Biology segment, showing strong
The drop in GAAP EPS from
First Quarter FY2025 Highlights
- First quarter organic revenue increased by
4% (5% reported) to$289.5 million
- GAAP earnings per share (EPS) was
$0.21 $0.31 $0.42 $0.41
- Continued adoption and utilization across the Diagnostics & Spatial Biology ("DSS"), formerly Diagnostics & Genomics, portfolio led to
14% organic segment growth (14% reported).
- Continued uptake of our cell and gene therapy workflow solutions, including strong growth in our GMP reagent offerings.
The Company's financial statements are prepared in accordance with accounting principles generally accepted in
"The start to fiscal 2025 was largely consistent with our expectations, as a high-level of execution by the Bio-Techne team drove continued momentum across our Diagnostics & Spatial Biology segment," said Kim Kelderman, President and Chief Executive Officer of Bio-Techne. "This was augmented by strong results in our cell and gene therapy business, including robust growth in our GMP reagent portfolio. The strength in cell and gene therapy, combined with favorable year-to-date funding dynamics, gives us increased confidence in the forthcoming recovery in our biotech end market."
Kelderman added, "Our growth pillars, as well as our core portfolio, continue to outperform in what has proven to be a prolonged period of challenges facing the industry. The high value this novel portfolio brings to our research and clinical diagnostics customers positions the business for an even stronger future. We remain focused on delivering the solutions our customers rely on to catalyze advances in science and medicine while creating value for all our stakeholders."
Bio-Techne will host an earnings conference call today, October 30, 2024 at 8:00 a.m. CDT. To listen, please dial 1-877-407-9208 or 1-201-493-6784 for international callers, and reference conference ID 13749405. The earnings call can also be accessed via webcast through the following link https://investors.bio-techne.com/ir-calendar.
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512- 2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 13749405. The replay will be available from 11:00 a.m. CDT on Wednesday, October 30, 2024, until 11:00 p.m. CST on Saturday, November 30, 2024.
First Quarter Fiscal 2025
Revenue
Net sales for the first quarter increased
GAAP Earnings Results
GAAP EPS was
Non-GAAP Earnings Results
Adjusted EPS increased to
Segment Results
Management uses adjusted operating results to monitor and evaluate performance of the Company's business segments, as highlighted below.
Protein Sciences Segment
The Company's Protein Sciences segment is one of the world's leading suppliers of specialized proteins such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology and academic research communities. Additionally, the segment provides an array of platforms useful in various areas of protein analysis. Protein Sciences segment's first quarter fiscal 2025 net sales were
Diagnostics and Spatial Biology Segment (formerly Diagnostics and Genomics Segment)
The Company's Diagnostics and Spatial Biology segment provides blood chemistry and blood gas quality controls, hematology instrument controls, immunoassays and other bulk and custom reagents for the in vitro diagnostic market. The Diagnostics and Spatial Biology segment also develops and provides spatial biology products as well as exosome-based diagnostics for various pathologies, including prostate cancer. The Diagnostics and Spatial Biology segment's first quarter fiscal 2025 net sales were
Use of non-GAAP Adjusted Financial Measures:
This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the
- Organic growth
- Adjusted diluted earnings per share
- Adjusted net earnings
- Adjusted tax rate
- Adjusted gross margin
- Adjusted operating income
- Adjusted operating margin
- Earnings before interest, taxes, depreciation, and amortization (EBITDA)
- Adjusted EBITDA
We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.
Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, the impact of businesses held-for-sale, as well as the impact of partially-owned consolidated subsidiaries. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods. Revenues from partially-owned subsidiaries consolidated in our financial statements are also excluded from our organic revenue calculation, as those revenues are not fully attributable to the Company. There was no revenue from partially-owned consolidated subsidiaries in fiscal year 2024 or fiscal year 2025.
Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjection assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to partially-owned consolidated subsidiaries as well as revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.
The Company's non-GAAP adjusted operating margin, adjusted EBITDA, and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, and other non-recurring items including certain costs related to the transition to a new CEO, goodwill and long-lived asset impairments, and gains. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition.
The Company's non-GAAP adjusted EBITDA and adjusted net earnings, in total and on a per share basis, also excludes gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired in the future) and certain adjustments to income tax expense. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.
Investors are encouraged to review the reconciliations of adjusted financial measures used in this press release to their most directly comparable GAAP financial measures as provided with the financial statements attached to this press release.
Forward Looking Statements:
Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the effect of new branding and marketing initiatives, the integration of new businesses and leadership, the introduction and acceptance of new products, the funding and focus of the types of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.
For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise any forward-looking statements we make in our press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately
Contact: | David Clair, Vice President, Investor Relations & Corporate Development |
David.Clair@bio-techne.com | |
612-656-4416 |
BIO-TECHNE CORPORATION CONSOLIDATED STATEMENTS OF EARNINGS (In thousands, except per share data) (Unaudited) | |||||||
QUARTER | |||||||
ENDED | |||||||
9/30/2024 | 9/30/2023 | ||||||
Net Sales | $ | 289,458 | $ | 276,935 | |||
Cost of sales | 106,441 | 91,744 | |||||
Gross margin | 183,017 | 185,191 | |||||
Operating Expenses: | |||||||
Selling, general and administrative | 119,161 | 105,331 | |||||
Research and development | 23,869 | 23,998 | |||||
Total Operating Expenses | 143,030 | 129,329 | |||||
Operating income | 39,987 | 55,862 | |||||
Other income (expense) | 184 | (6,304) | |||||
Earnings before income taxes | 40,171 | 49,558 | |||||
Income taxes | 6,571 | (1,435) | |||||
Net earnings | $ | 33,600 | $ | 50,993 | |||
Earnings per share: | |||||||
Basic | $ | 0.21 | $ | 0.32 | |||
Diluted | $ | 0.21 | $ | 0.31 | |||
Weighted average common shares outstanding | |||||||
Basic | 158,531 | 158,130 | |||||
Diluted | 161,115 | 161,940 | |||||
BIO-TECHNE CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (In thousands) (Unaudited) | ||||||
9/30/2024 | 6/30/2024 | |||||
ASSETS | ||||||
Cash and equivalents | $ | 187,540 | $ | 151,791 | ||
Short-term available-for-sale investments | — | 1,072 | ||||
Accounts receivable, net | 223,688 | 241,394 | ||||
Inventories | 185,041 | 179,731 | ||||
Current assets held-for-sale | 9,459 | 9,773 | ||||
Other current assets | 42,839 | 33,658 | ||||
Total current assets | 648,567 | 617,419 | ||||
Property and equipment, net | 253,939 | 251,154 | ||||
Right of use assets | 89,221 | 91,285 | ||||
Goodwill and intangible assets, net | 1,468,589 | 1,479,744 | ||||
Other assets | 275,701 | 264,265 | ||||
Total assets | $ | 2,736,017 | $ | 2,703,867 | ||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
Accounts payable and accrued expenses | $ | 94,624 | $ | 112,672 | ||
Contract liabilities | 26,614 | 27,930 | ||||
Income taxes payable | 3,136 | 3,706 | ||||
Operating lease liabilities - current | 13,485 | 12,920 | ||||
Other current liabilities | 4,269 | 2,151 | ||||
Total current liabilities | 142,128 | 159,379 | ||||
Deferred income taxes | 50,017 | 55,863 | ||||
Long-term debt obligations | 300,000 | 319,000 | ||||
Operating lease liabilities | 85,433 | 87,618 | ||||
Other long-term liabilities | 19,789 | 13,157 | ||||
Stockholders' equity | 2,138,650 | 2,068,850 | ||||
Total liabilities and stockholders' equity | $ | 2,736,017 | $ | 2,703,867 | ||
BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED GROSS MARGIN PERCENTAGE (In thousands) (Unaudited) | |||||||
QUARTER | |||||||
ENDED | |||||||
9/30/2024 | 9/30/2023 | ||||||
Total consolidated net sales | $ | 289,458 | $ | 276,935 | |||
Business held-for-sale1) | 2,303 | — | |||||
Revenue from recurring operations | $ | 287,155 | $ | 276,935 | |||
Gross margin - GAAP | $ | 183,017 | $ | 185,191 | |||
Gross margin percentage - GAAP | 63.2 | % | 66.9 | % | |||
Identified adjustments: | |||||||
Costs recognized upon sale of acquired inventory | $ | 188 | $ | 181 | |||
Amortization of intangibles | 11,779 | 11,866 | |||||
Stock-based compensation, inclusive of employer taxes | 272 | 214 | |||||
Restructuring and restructuring-related costs | 4,898 | — | |||||
Impact of business held-for-sale1) | (558) | — | |||||
Adjusted gross margin | $ | 199,596 | $ | 197,452 | |||
Adjusted gross margin percentage2) | 69.5 | % | 71.3 | % | |||
1) | Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
2) | Adjusted gross margin percentage excludes both |
BIO-TECHNE CORPORATION RECONCILIATION OF ADJUSTED OPERATING MARGIN PERCENTAGE (In thousands) (Unaudited) | |||||||
QUARTER | |||||||
ENDED | |||||||
9/30/2024 | 9/30/2023 | ||||||
Total consolidated net sales | $ | 289,458 | $ | 276,935 | |||
Business held-for-sale1) | 2,303 | — | |||||
Revenue from recurring operations | $ | 287,155 | $ | 276,935 | |||
Operating income - GAAP | $ | 39,987 | $ | 55,862 | |||
Operating income percentage - GAAP | 13.8 | % | 20.2 | % | |||
Identified adjustments: | |||||||
Costs recognized upon sale of acquired inventory | $ | 188 | $ | 181 | |||
Amortization of intangibles | 19,741 | 19,851 | |||||
Acquisition related expenses and other | 1,513 | (588) | |||||
Certain litigation charges | 292 | — | |||||
Stock-based compensation, inclusive of employer taxes | 10,637 | 11,494 | |||||
Restructuring and restructuring-related costs | 11,022 | 89 | |||||
Impact of business held-for-sale1) | (148) | — | |||||
Adjusted operating income | $ | 83,232 | $ | 86,889 | |||
Adjusted operating margin percentage2) | 29.0 | % | 31.4 | % | |||
1) | Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
2) | Adjusted operating margin percentage excludes both |
BIO-TECHNE CORPORATION NON-GAAP ADJUSTED CONSOLIDATED NET EARNINGS and EARNINGS per SHARE (In thousands, except per share data) (Unaudited) | |||||||
QUARTER | |||||||
ENDED | |||||||
9/30/2024 | 9/30/2023 | ||||||
Net earnings before taxes - GAAP | $ | 40,171 | $ | 49,558 | |||
Identified adjustments: | |||||||
Costs recognized upon sale of acquired inventory | 188 | 181 | |||||
Amortization of intangibles | 19,741 | 19,851 | |||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 2,490 | 4,208 | |||||
Acquisition related expenses and other | 1,674 | (442) | |||||
Certain litigation charges | 292 | — | |||||
Stock-based compensation, inclusive of employer taxes | 10,637 | 11,494 | |||||
Restructuring and restructuring-related costs | 11,022 | 89 | |||||
Investment (gain) loss and other non-operating | — | (283) | |||||
Impact of business held-for-sale1) | (148) | — | |||||
Net earnings before taxes - Adjusted | $ | 86,067 | $ | 84,656 | |||
Non-GAAP tax rate | 21.5 | % | 22.0 | % | |||
Non-GAAP tax expense | $ | 18,536 | $ | 18,615 | |||
Non-GAAP adjusted net earnings | $ | 67,531 | $ | 66,041 | |||
Earnings per share - diluted - Adjusted | $ | 0.42 | $ | 0.41 | |||
1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION NON-GAAP adjusted tax rate (In percentages) (Unaudited) | |||||||
QUARTER | |||||||
ENDED | |||||||
9/30/2024 | 9/30/2023 | ||||||
GAAP effective tax rate | 16.4 | % | (2.9) | % | |||
Discrete items | 7.2 | 27.4 | |||||
Long-term GAAP tax rate | 23.6 | % | 24.5 | % | |||
Rate impact items | |||||||
Stock based compensation | (2.8) | % | (2.7) | % | |||
Other | 0.7 | 0.2 | |||||
Total rate impact items | (2.1) | % | (2.5) | % | |||
Non-GAAP adjusted tax rate | 21.5 | % | 22.0 | % | |||
BIO-TECHNE CORPORATION SEGMENT REVENUE (In thousands) (Unaudited) | ||||||
QUARTER | ||||||
ENDED | ||||||
9/30/2024 | 9/30/2023 | |||||
Protein Sciences segment revenue | $ | 204,535 | $ | 204,655 | ||
Diagnostics and Spatial Biology segment revenue | 83,192 | 72,797 | ||||
Other revenue1) | 2,303 | — | ||||
lntersegment revenue | (572) | (517) | ||||
Consolidated revenue | $ | 289,458 | $ | 276,935 | ||
1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION SEGMENT OPERATING INCOME (In thousands) (Unaudited) | ||||||
QUARTER | ||||||
ENDED | ||||||
9/30/2024 | 9/30/2023 | |||||
Protein Sciences segment operating income | $ | 80,541 | $ | 88,361 | ||
Diagnostics and Spatial Biology segment operating income | 4,277 | 527 | ||||
Segment operating income | 84,818 | 88,888 | ||||
Corporate general, selling, and administrative | (1,586) | (1,999) | ||||
Adjusted operating income | 83,232 | 86,889 | ||||
Cost recognized upon sale of acquired inventory | (188) | (181) | ||||
Amortization of intangibles | (19,741) | (19,851) | ||||
Acquisition related expenses and other | (1,513) | 588 | ||||
Certain litigation charges | (292) | — | ||||
Stock-based compensation, inclusive of employer taxes | (10,637) | (11,494) | ||||
Restructuring and restructuring-related costs | (11,022) | (89) | ||||
Impact of business held-for-sale1) | 148 | — | ||||
Operating income | $ | 39,987 | $ | 55,862 | ||
1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
BIO-TECHNE CORPORATTON RECONCILIATION OF GAAP NET INCOME TO ADJUSTED EBITDA (In thousands) (Unaudited) | ||||||
QUARTER | ||||||
ENDED | ||||||
9/30/2024 | 9/30/2023 | |||||
Net earnings | $ | 33,600 | $ | 50,993 | ||
Net interest expense (income) | 1,250 | 4,003 | ||||
Depreciation and amortization | 28,137 | 28,540 | ||||
Income taxes | 6,571 | (1,435) | ||||
EBITDA | 69,558 | 82,101 | ||||
Costs recognized upon sale of acquired inventory | 188 | 181 | ||||
Amortization of Wilson Wolf intangible assets and acquired inventory | 2,490 | 4,208 | ||||
Acquisition related expenses and other | 1,674 | (442) | ||||
Certain litigation charges | 292 | — | ||||
Stock-based compensation, inclusive of employer taxes | 10,637 | 11,494 | ||||
Restructuring and restructuring-related costs | 11,022 | 89 | ||||
Investment (gain) loss and other non-operating | — | (283) | ||||
Impact of business held-for-sale1) | (148) | — | ||||
Adjusted EBITDA | $ | 95,713 | $ | 97,348 | ||
1) Since December 31, 2023, the Company has a business that has met the held-for-sale criteria. |
BIO-TECHNE CORPORATION CONDENSED CASH FLOW (In thousands) (Unaudited) | ||||||
QUARTER | ||||||
ENDED | ||||||
9/30/2024 | 9/30/2023 | |||||
CASH FLOWS FROM OPERATING ACTIVITIES | ||||||
Net earnings | $ | 33,600 | $ | 50,993 | ||
Adjustments to reconcile net earnings to net cash provided by operating activities | ||||||
Depreciation and amortization | 28,137 | 28,540 | ||||
Costs recognized on sale of acquired inventory | 188 | 181 | ||||
Deferred income taxes | (5,340) | (11,591) | ||||
Stock-based compensation expense | 10,184 | 10,093 | ||||
Fair value adjustment to available-for-sale investments | — | (283) | ||||
(Gain) Loss on equity method investment | (374) | 2,382 | ||||
Asset impairment restructuring | 6,039 | — | ||||
Fair value adjustment to contingent consideration payable | — | (1,750) | ||||
Other operating activities | (8,545) | (19,182) | ||||
Net cash provided by (used in) operating activities | 63,889 | 59,383 | ||||
CASH FLOWS FROM INVESTING ACTIVITIES | ||||||
Proceeds from sale of available-for-sale investments | 1,085 | 23,759 | ||||
Additions to property and equipment | (9,172) | (13,592) | ||||
Acquisitions, net of cash acquired | — | (166,426) | ||||
Distributions from (Investments in) Wilson Wolf | 1,403 | 2,149 | ||||
Investment in Spear Bio | (15,000) | — | ||||
Net cash provided by (used in) investing activities | (21,684) | (154,110) | ||||
CASH FLOWS FROM FINANCING ACTIVITIES | ||||||
Cash dividends | (12,688) | (12,654) | ||||
Proceeds from stock option exercises | 25,101 | 14,394 | ||||
Long-term debt activity, net | (19,000) | 90,000 | ||||
Taxes paid on RSUs and net share settlements | (4,984) | (20,228) | ||||
Net cash provided by (used in) financing activities | (11,571) | 71,512 | ||||
Effect of exchange rate changes on cash and cash equivalents | 5,115 | (8,693) | ||||
Net increase (decrease) in cash and cash equivalents | 35,749 | (31,908) | ||||
Cash and cash equivalents at beginning of period | 151,791 | 180,571 | ||||
Cash and cash equivalents at end of period | $ | 187,540 | $ | 148,663 | ||
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-releases-first-quarter-fiscal-2025-results-302290915.html
SOURCE Bio-Techne Corporation
FAQ
What was Bio-Techne's (TECH) revenue growth in Q1 2025?
How did Bio-Techne's (TECH) EPS perform in Q1 2025?
What was Bio-Techne's (TECH) Diagnostics & Spatial Biology segment growth in Q1 2025?
How did Bio-Techne's (TECH) operating margins change in Q1 2025?
